An Expanded Access IND to Evaluate the Safety and Efficacy of Autologous HBadMSCs for the Treatment of a Single Pediatric Patient With Congenital Muscular Dystrophy.

This Expanded Access includes an up to 28 days screening period, a 44-week Treatment Period, and a 52-week Safety Follow-up Period. All periods are associated with evaluations and procedures that must be performed at specific time points.

-Screening

At the Screening Visit (Visit 1), the study's participant information will be collected by delegated personnel to evaluate trial eligibility. The following information is required to determine eligibility:

• Parent Permission before any trial-related activities.
• Collection of demographic information, such as age, race, ethnicity, date of birth, gender, and relevant medical and surgical history.
• Collection of Medical History and concomitant medications, including relevant information about study participants' past and present health.
• Inclusion and Exclusion criteria evaluation.
• Measurement of vital signs includes respiratory rate, body temperature, blood pressure, pulse rate, oxygen saturation, and weight and height measurement.
• Blood chemistry, Coagulation panel, Inflammatory Markers, & Hematology.
• Physical examination by Principal Investigator.

Within 28 days of the Visit 1 - Screening, the principal investigator must decide the participant's eligibility. Once the principal investigator has confirmed the subject's eligibility, the subject will be scheduled to receive Infusion 1.